

Introduction into machine learning and analysis of Breast Cancer Proteomes

Theme09 - Introduction to Machine Learning

Mats Slik

344216

BFV3

October 5, 2022

Dave Langers (LADR)

Bart Barnard (BABA)

Introduction into machine learning and analysis of Breast Cancer Proteomes

Theme09 - Introduction to Machine Learning

Mats Slik

344216

Bioinformatics

Institute for Life Science & Technology

Hanze University of Applied Sciences

Dave Langers (LADR)

Bart Barnard (BABA)

October 5, 2022

Abstract

the data were used to assess how the mutations in the DNA are affecting the protein expression landscape in breast cancer. Genes in our DNA are first transcribed into RNA molecules which then are translated into proteins. Changing the information content of DNA has impact on the behavior of the proteome, which is the main functional unit of cells, taking care of cell division, DNA repair, enzymatic reactions and signaling etc. my question is: Are there different ways to categorize breast cancer based on protein expression data, with machine learning being used to classify them without using the pam50 proteins?

Table of Contents

Abstract	i
List of Abbreviations	iii
List of Figures	iii
List of Tables	iii
1 Introduction	1
2 Methods	2
3 Results	3
4 Discussion and Conclusion	8
5 References	9
6 Appendices	10

List of Abbreviations

EDA	Exploratory Data Analysis
TCGA	The cancer Genome Atlas Program
CPTAC	Clinical Proteomic Tumor Analysis Consortium
DNA	Deoxyribonucleic Acid
RNA	Ribonucleic Acid

List of Figures

1	figure 1	3
2	figure 2	4
3	figure 3	5
4	figure 4	6
5	distribution of amount of samples per tumor stage	7

List of Tables

1 Introduction

??

2 Methods

3 Results

When looking at the dimensions of the data set we can see there are allot of proteins see table 1

Row.names	Tumor	Tumor..T1.Coded	AJCC.Stage	Vital.Status	NP_958782
TCGA-A2-A0CM	T2	T_Other	Stage IIA	DECEASED	0.6834
TCGA-A2-A0D2	T2	T_Other	Stage IIB	LIVING	0.1075
TCGA-A2-A0EQ	T2	T_Other	Stage IIA	LIVING	-0.9127
TCGA-A2-A0EV	T1	T1	Stage IA	LIVING	0.453
TCGA-A2-A0EX	T3	T_Other	Stage IIB	LIVING	1.185
TCGA-A2-A0EY	T2	T_Other	Stage IIB	LIVING	1.175

number of rows: 77 number of columns: 9204

after this first assessment of the data we started looking at the number of missing values as seen in the figures' fig 1 and 2 below




Figure 1: figure 1

as we can see in these figures 1 and 2 the distribution is very much to the left where a lot of proteins have one or only two missing values, further more there are still a couple of proteins that have a high number of missing values these are to be filtered out because this can create a false set of results when we are using




Figure 2: figure 2

them in our machine learning algorithm for clustering them o there cancer stage. so to further see how the data is we took the distribution of a couple of proteins in a multi boxplot as seen in figure 3




Figure 3: figure 3

in this figure 3 we can clearly see that for the first 70 protein that most have a distribution of their log2 itraq expression between 5 and -5 but there are some that have higher numbers. to further make sense of all the 12 to 9 thousand proteins in the data we calculated the standard deviation of them see figure 4

in this figure 4 we compared the normal data set and the one filterd that has had protein with more tha 10% of their values missing removed. in it we can clearly see that a lot of proteins with high deviation are removed from the data. to make a further analyse of these samples

in this figure 5 we can see how the diffrent samples are spread according to there cancer stages.




Figure 4: figure 4




Figure 5: distribution of amount of samples per tumor stage

4 Discussion and Conclusion

in the results section we can see from the figures 1 and two that although the data set was supplied with the label as high quality there are still proteins in the data with more than 10% of their expression values missing, this combined with the need for using the expression data with the clinical categorical data, the sample names needed to be changed to be compared. all this wasn't something to be expecting of high quality data. also in figure 5 it is clearly visible that the categorisation of the tumor stage there are a lot of T2 stages in the samples than any other.

5 References

Mertins, Philipp, D R Mani, Kelly Ruggles, Michael Gillette, Karl Clauser, Pei Wang, Xianlong Wang, et al. 2016. “Proteogenomics Connects Somatic Mutations to Signaling in Breast Cancer.” *Nature* 534 (May). <https://doi.org/10.1038/nature18003>.

6 Appendices